Genitourinary/Sexual Health

Genitourinary (GU) conditions account for a major source of distress for millions of people throughout the world. While many GU conditions are manageable, patients often do not seek treatment due to either the dismissal of these conditions as "merely quality of life" issues, or the embarrassment and misunderstanding associated with their symptoms and conditions. In response, Pfizer is working to help these patients. Our goal is to restore dignity to those suffering from GU conditions and help improve their quality of life.

Genitourinary/Sexual Health Conditions

Indications for medicines currently in phases of development, from Phase 1 through to recent approval:

• Endometriosis – A condition in which tissues of endometrial origin (the lining of the uterus) grow outside of the uterus and cause a variety of symptoms. Some of the resulting symptoms may be gynaecological (e.g. bleeding, pain, infertility) and some may be cyclical.
• Female Sexual Dysfunction (FSD) – A collective term used for a group of conditions affecting women's sexual desire, their ability to achieve (or sustain) a feeling of arousal, their ability to orgasm and/or the experience of pain during intercourse. FSD affects an estimated 40 percent of women worldwide. Pfizer is working to discover a novel treatment for women who are distressed by this condition.
• Interstitial Cystitis – A condition of the bladder in which pain is a predominant feature and may be accompanied with other urinary symptoms.
• Lower Urinary Tract Symptoms – The collective term for an overlapping set of symptoms caused by benign prostatic hyperplasia (non-cancerous enlargement of the prostate gland) and/or overactive bladder. These symptoms include increased urgency and frequency of needing to pass urine; the need to go to the bathroom two or more times a night (nocturia); incontinence; poor urine flow and straining to pass urine. These symptoms have a profound impact on the quality of life of millions of patients worldwide, often leading to social isolation, depression, lack of sleep, and acute embarrassment. Pfizer is working to better understand patients' needs in order to help create a more patient-centric, symptom-related diagnosis, as well as novel treatments to relieve patients' most bothersome symptoms.
• Overactive Bladder – A condition characterised by increased urgency and frequency of needing to pass urine, sometimes accompanied by incontinence or leakage of urine.

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.